open access
Vol 26, No 1 (2019)
Letter to the Editor
Submitted: 2019-01-21
Accepted: 2019-01-21
Published online: 2019-03-14
Get Citation
Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update
1, 2, 3
Affiliations- Department of Medical and Surgical Sciences, University of Bologna, Italy
- Department of Hypertension and Diabetology, Medical University of Gdansk, Poland
- Università Milano-Bicocca, Milan, Italy
open access
Vol 26, No 1 (2019)
Letters to the Editors
Submitted: 2019-01-21
Accepted: 2019-01-21
Published online: 2019-03-14
Abstract
Not available
Abstract
Not available
Get Citation
About this articleTitle
Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update
Journal
Issue
Article type
Letter to the Editor
Pages
99-101
Published online
2019-03-14
Page views
2629
Article views/downloads
1350
DOI
10.5603/CJ.2019.0015
Pubmed
Bibliographic record
Cardiol J 2019;26(1):99-101.
Authors
Claudio Borghi
Krzysztof Narkiewicz
Giuseppe Mancia
References (13)- Kuo CF, Grainge MJ, Zhang W, et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015; 11(11): 649–662.
- Johnson RJ, Bakris GL, Borghi C, et al. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. Am J Kidney Dis. 2018; 71(6): 851–865.
- Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014; 26(2): 186–191.
- Johnson RJ, Titte S, Cade JR, et al. Uric acid, evolution and primitive cultures. Semin Nephrol. 2005; 25(1): 3–8.
- Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76(1): 29–42.
- Borghi C, Tykarski A, Widecka K, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J. 2018; 25(5): 545–563.
- Borghi C, Perez-Ruiz F. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2016; 20(5): 983–992.
- White WB, Saag KG, Becker MA, et al. CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018; 378(13): 1200–1210.
- Richette P, Latourte A, Bardin T. Cardiac and renal protective effects of urate-lowering therapy. Rheumatology (Oxford). 2018; 57(suppl_1): i47–i50.
- Kojima S, Matsui K, Ogawa H, et al. Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. J Cardiol. 2017; 69(1): 169–175.
- Kimura K, Hosoya T, Uchida S, et al. FEATHER Study Investigators. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Am J Kidney Dis. 2018; 72(6): 798–810.
- Zhang M, Solomon DH, Desai RJ, et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol. Circulation. 2018; 138(11): 1116–1126.
- White WB. Gout, xanthine oxidase inhibition, and cardiovascular outcomes. Circulation. 2018; 138(11): 1127–1129.
